Press Releases
At Pulmatrix, we are committed to communicating clear and consistent information. Here we feature current and historic content concerning our science, our pipeline, and our corporate initiatives and achievements. Please check in often for the most recent press releases and information.
Apr 15, 2019- Transaction marks Cipla's entry into specialty respiratory segment, building on inroads made into the specialty business in the recent pastPulmatrix, Inc. (NASDAQ: PULM; hereafter referred to as "Pulmatrix"), a clinical stage biopharmaceutical company focused on developing novel inhaled therapeutics to serve unmet needs in...
- Apr 8, 2019Underwriter Exercises In Full Option to Purchase Additional Securities
Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced the closing of its previously announced underwritten public offering of an aggregate of 1,719,554...
- Apr 3, 2019
Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced the pricing of its previously announced underwritten public offering of an aggregate of 10,666,666...
- Apr 1, 2019The Binding Term Sheet Executed on April 1, 2019 Lays Groundwork for Entry into a Definitive Agreement During the 2nd Quarter of 2019
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company focused on developing novel inhaled therapeutics to serve unmet needs in respiratory disease, announced today its entry...
- Mar 14, 2019
Pulmatrix, Inc. (NASDAQ: PULM) announced today that members of its management team will present/participate in investor meetings at the following upcoming conferences: Oppenheimer's 29th Annual...
